Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Clinical trial NCT00630110 · COMPLETED
Trial details
- NCT number
- NCT00630110
- Sponsor
- Nereus Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-02-01
- Primary completion
- 2011-06-01
- Enrollment
- 172
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.